{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:44:49Z","timestamp":1788371089044,"version":"build-2803163510"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejphar.2023.176032","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:09:51Z","timestamp":1693566591000},"page":"176032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A synopsis of multitarget therapeutic effects of anesthetics on depression"],"prefix":"10.1016","volume":"957","author":[{"given":"Guowei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176032_bib1","article-title":"Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial","volume":"376","author":"Abbar","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2023.176032_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ijnp\/pyz041","article-title":"(R)-Ketamine induces a greater increase in prefrontal 5-HT release than (S)-Ketamine and ketamine metabolites via an AMPA receptor-independent mechanism","volume":"22","author":"Ago","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s13063-018-2843-9","article-title":"The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ejphar.2023.176032_bib4","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.ejphar.2023.176032_bib5","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176032_bib6","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1038\/s41598-017-08166-9","article-title":"Isoflurane produces antidepressant effects and induces TrkB signaling in rodents","volume":"7","author":"Antila","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176032_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bdi.12967","article-title":"Latent class analysis of bipolar disorder symptoms and suicidal ideation and behaviors","volume":"23","author":"Au","year":"2021","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.176032_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2022.01.104","article-title":"mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression","volume":"303","author":"Averill","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/acps.12204","article-title":"First-episode types in bipolar disorder: predictive associations with later illness","volume":"129","author":"Baldessarini","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2023.176032_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpsychires.2023.06.028","article-title":"Arketamine for bipolar depression: open-label, dose-escalation, pilot study","volume":"164","author":"Bandeira","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-019-00623-5","article-title":"Revisiting tramadol: a multi-modal agent for pain management","volume":"33","author":"Barakat","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2023.176032_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/WNF.0000000000000517","article-title":"Effects of GRIN2B , GRIA1 , and BDNF polymorphisms on the therapeutic action of ketamine and esketamine in treatment-resistant depression patients: secondary analysis from a randomized clinical trial","volume":"45","author":"Beanes","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","article-title":"Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-Methyl-D-Aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies","volume":"39","author":"Bernstein","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00213-006-0464-6","article-title":"Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice","volume":"188","author":"Berrocoso","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ph15080997","article-title":"Pharmacological comparative characterization of REL-1017 (Esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-Methyl-D-Aspartate receptors","volume":"15","author":"Bettini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2023.176032_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11011-022-01095-1","article-title":"Targeting inflammation: a potential approach for the treatment of depression","volume":"38","author":"Bhatt","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ejphar.2023.176032_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2174\/1570159X18666201015155816","article-title":"5-HT(3) receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders","volume":"19","author":"Bhatt","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.863959","article-title":"REL-1017 (esmethadone), A novel NMDAR blocker for the treatment of MDD is not neurotoxic in sprague-dawley rats","volume":"13","author":"Bifari","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17460441.2017.1377697","article-title":"Discovery and development of tramadol for the treatment of pain","volume":"12","author":"Bravo","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejphar.2023.176032_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/cer-2022-0149","article-title":"Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study","volume":"11","author":"Brendle","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ejphar.2023.176032_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1021\/acsptsci.0c00132","article-title":"Low-dose tramadol as an off-label antidepressant: a data mining analysis from the patients' perspective","volume":"3","author":"Bumpus","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejphar.2023.176032_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.176032_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior","volume":"41","author":"Canuso","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-2007-1017040","article-title":"Open comparative study with treatment-refractory depressed patients: electroconvulsive therapy--anesthetic therapy with isoflurane (preliminary report)","volume":"21","author":"Carl","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2023.176032_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114749","article-title":"Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: a posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies","volume":"316","author":"Chen","year":"2022","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/a-1589-6301","article-title":"Baseline working memory predicted response to low-dose ketamine infusion in patients with treatment-resistant depression","volume":"55","author":"Chen","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00213-020-05737-z","article-title":"Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression","volume":"238","author":"Chen","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","article-title":"Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis","volume":"238","author":"Conley","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110507","article-title":"Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression","volume":"115","author":"De La Salle","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.671859","article-title":"REL-1017 (esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study","volume":"12","author":"De Martin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib36","first-page":"CD011612","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2023.176032_bib37","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder","volume":"10","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2023.176032_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2020.03.089","article-title":"A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression","volume":"271","author":"Dinoff","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JPR.S184782","article-title":"Patient-controlled intravenous tramadol versus patient-controlled intravenous hydromorphone for analgesia after secondary cesarean delivery: a randomized controlled trial to compare analgesic, anti-anxiety and anti-depression effects","volume":"12","author":"Duan","year":"2019","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022538","article-title":"Protocol for a randomised, double-blind, placebo-controlled trial to explore the effect of tramadol in the prevention of postpartum depression (ETPPD)","volume":"8","author":"Duan","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2023.176032_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000511348","article-title":"Psychotic depression: diagnosis, differential diagnosis, and treatment","volume":"90","author":"Dubovsky","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.ejphar.2023.176032_bib43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2020.20010018","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial","volume":"178","author":"Dwyer","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT)","volume":"25","author":"Ekstrand","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.986378","article-title":"Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: a case report","volume":"13","author":"Elkrief","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib47","first-page":"113","article-title":"Intra-individual open comparison of burst-suppression-isoflurane-anaesthesia versus electroconvulsive therapy in the treatment of severe depression","volume":"10","author":"Engelhardt","year":"1993","journal-title":"Eur. J. Anaesthesiol."},{"key":"10.1016\/j.ejphar.2023.176032_bib48","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bdi.13284","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"25","author":"Fancy","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib50","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression","volume":"45","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2004.08.011","article-title":"Long-term exposure of rats to tramadol alters brain dopamine and alpha 1-adrenoceptor function that may be related to antidepressant potency","volume":"501","author":"Faron-Gorecka","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","article-title":"REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial","volume":"179","author":"Fava","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib53","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jad.2023.05.041","article-title":"Self-stigma and bipolar disorder: a systematic review and best-evidence synthesis","volume":"335","author":"Favre","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euroneuro.2021.04.024","article-title":"The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: results from a randomized double-blind study","volume":"49","author":"Feeney","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2023.176032_bib56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/JCP.0000000000001265","article-title":"Nitrous oxide (N2O) as a treatment for refractory depression: a word of caution","volume":"40","author":"Fluegge","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib57","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","article-title":"N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects","volume":"44","author":"Fogaca","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","article-title":"Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders","volume":"178","author":"Forte","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1037\/bul0000084","article-title":"Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research","volume":"143","author":"Franklin","year":"2017","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.ejphar.2023.176032_bib60","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib61","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.12688\/hrbopenres.13182.1","article-title":"Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)","volume":"3","author":"Gallagher","year":"2020","journal-title":"HRB Open Res"},{"key":"10.1016\/j.ejphar.2023.176032_bib63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00124509-200112000-00009","article-title":"Inefficacy of burst-suppression anesthesia in medication-resistant major depression: a controlled trial","volume":"17","author":"Garcia-Toro","year":"2001","journal-title":"J. ECT"},{"key":"10.1016\/j.ejphar.2023.176032_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1874473711666181008163107","article-title":"Mini-review: a brief history of nitrous oxide (N2O) use in neuropsychiatry","volume":"11","author":"Gillman","year":"2019","journal-title":"Curr Drug Res Rev"},{"key":"10.1016\/j.ejphar.2023.176032_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/1440-1681.13737","article-title":"Intranasal (2R, 6R)-hydroxynorketamine for acute pain: behavioural and neurophysiological safety analysis in mice","volume":"50","author":"Goswami","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2023.176032_bib66","first-page":"269","article-title":"Isoflurane anesthesia therapy: a replacement for ECT in depressive disorders?","volume":"3","author":"Greenberg","year":"1987","journal-title":"Convuls Ther."},{"key":"10.1016\/j.ejphar.2023.176032_bib67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12487","article-title":"Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial","volume":"19","author":"Grunebaum","year":"2017","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib69","article-title":"Subanalysis of subjective cognitive measures from a phase 2, double-blind, randomized trial of REL-1017 in patients with major depressive disorder","volume":"25","author":"Guidetti","year":"2023","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.ejphar.2023.176032_bib70","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1590\/1516-4446-2020-1543","article-title":"Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial","volume":"43","author":"Guimaraes","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/dna.2019.4745","article-title":"The effects of propofol on autophagy","volume":"39","author":"Guo","year":"2020","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ejphar.2023.176032_bib72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1037\/pha0000310","article-title":"The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats","volume":"28","author":"Hanania","year":"2020","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.ejphar.2023.176032_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15055-3","article-title":"REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats","volume":"12","author":"Henningfield","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176032_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib76","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acschemneuro.1c00761","article-title":"Hydroxynorketamine pharmacokinetics and antidepressant behavioral effects of (2,6)- and (5r)-methyl-(2R,6R)-hydroxynorketamines","volume":"13","author":"Highland","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176032_bib77","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jad.2021.12.055","article-title":"Ketamine vs midazolam: mood improvement reduces suicidal ideation in depression","volume":"300","author":"Hochschild","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1254\/fpj.22141","article-title":"[Contribution of serotonin 5-HT(2A) receptor to antidepressant effect of serotonergic psychedelics]","volume":"158","author":"Ibi","year":"2023","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejphar.2023.176032_bib79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pbb.2010.02.011","article-title":"Evidence for the involvement of the noradrenergic system, dopaminergic and imidazoline receptors in the antidepressant-like effect of tramadol in mice","volume":"95","author":"Jesse","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2023.176032_bib81","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","article-title":"Understanding the pathophysiology of depression: from monoamines to the neurogenesis hypothesis model - are we there yet?","volume":"341","author":"Jesulola","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JCP.0000000000001317","article-title":"A systematic review on the efficacy of intravenous racemic ketamine for bipolar depression","volume":"41","author":"Joseph","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib83","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12888-022-03838-x","article-title":"BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model","volume":"22","author":"Ju","year":"2022","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib84","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176032_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bdi.13288","article-title":"Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: focus on cerebrovascular target engagement","volume":"25","author":"Kim","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib87","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1007\/s12035-018-1364-6","article-title":"Cortical excitability and activation of TrkB signaling during rebound slow oscillations are critical for rapid antidepressant responses","volume":"56","author":"Kohtala","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2023.176032_bib88","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1586\/17512433.2016.1141047","article-title":"Buprenorphine--the unique opioid adjuvant in regional anesthesia","volume":"9","author":"Kosel","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib90","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000119190","article-title":"Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment","volume":"31","author":"Langer","year":"1995","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejphar.2023.176032_bib91","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000118216","article-title":"Rapid psychotherapeutic effects of anesthesia with isoflurane (ES narcotherapy) in treatment-refractory depressed patients","volume":"14","author":"Langer","year":"1985","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejphar.2023.176032_bib92","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176032_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2015.09.037","article-title":"Propofol effects on cerebellar long-term depression","volume":"609","author":"Lee","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2023.176032_bib95","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","article-title":"Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial","volume":"47","author":"Lijffijt","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","article-title":"Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study","volume":"126","author":"Liu","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib97","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/npp.2013.128","article-title":"GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine","volume":"38","author":"Liu","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib98","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fpsyt.2020.00837","article-title":"Repeated nitrous oxide exposure exerts antidepressant-like effects through neuronal nitric oxide synthase activation in the medial prefrontal cortex","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib99","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176032_bib100","doi-asserted-by":"crossref","DOI":"10.1007\/s10877-023-00986-7","article-title":"Clinical validation of an adapted Eleveld Model for high-dose propofol treatments for depression","author":"Lybbert","year":"2023","journal-title":"J. Clin. Monit. Comput."},{"key":"10.1016\/j.ejphar.2023.176032_bib101","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.176032_bib102","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib103","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/ijnp\/pyy085","article-title":"Propofol for treatment-resistant depression: a pilot study","volume":"21","author":"Mickey","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib104","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","article-title":"Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in alpha7 nicotinic acetylcholine receptors","volume":"698","author":"Moaddel","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpsychires.2021.02.053","article-title":"Estimating the risk of suicide associated with mental disorders: a systematic review and meta-regression analysis","volume":"137","author":"Moitra","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib106","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/phar.2707","article-title":"Safety and effectiveness of NMDA receptor antagonists for depression: a multidisciplinary review","volume":"42","author":"Moore","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2023.176032_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1376","article-title":"A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression","volume":"13","author":"Nagele","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2023.176032_bib108","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2023.176032_bib109","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","article-title":"Midazolam and other benzodiazepines","author":"Olkkola","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(25)11430-4","article-title":"Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.176032_bib111","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/acps.13216","article-title":"The effects of ketamine on typical and atypical depressive symptoms","volume":"142","author":"Park","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2023.176032_bib112","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2023.04.019","article-title":"Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: a case series","volume":"333","author":"Payette","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","article-title":"Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies","volume":"199","author":"Pham","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2023.176032_bib114","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1176\/appi.ajp.20220216","article-title":"A novel, brief, fully automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial","volume":"179","author":"Price","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pbb.2015.10.005","article-title":"Translocator protein mediates the anxiolytic and antidepressant effects of midazolam","volume":"139","author":"Qiu","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2023.176032_bib116","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpsychires.2023.03.037","article-title":"The efficacy and safety of buprenorphine for the treatment of depression: a systematic review and meta-analysis","volume":"161","author":"Riblet","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib117","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41386-019-0443-3","article-title":"(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism","volume":"45","author":"Riggs","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib118","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","article-title":"A role for the mu opioid receptor in the antidepressant effects of buprenorphine","volume":"319","author":"Robinson","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1092852922000773","article-title":"Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities","volume":"28","author":"Rocha","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejphar.2023.176032_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-018-0584-7","article-title":"Opioidergic agents as antidepressants: rationale and promise","volume":"33","author":"Saxena","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2023.176032_bib121","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41386-022-01290-9","article-title":"Shared and disease-sensitive dysfunction across bipolar and unipolar disorder during depressive episodes: a transdiagnostic study","volume":"47","author":"Shao","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biopsych.2020.12.006","article-title":"Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities","volume":"90","author":"Shinohara","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib124","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/02698811221084055","article-title":"The antidepressant effect and safety of non-intranasal esketamine: a systematic review","volume":"36","author":"Smith-Apeldoorn","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012196","article-title":"Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling","volume":"23","author":"Stahl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176032_bib127","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11920-013-0431-y","article-title":"Options for pharmacological treatment of refractory bipolar depression","volume":"16","author":"Tondo","year":"2014","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.ejphar.2023.176032_bib129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/0929867003375335","article-title":"Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery","volume":"7","author":"Trapani","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176032_bib130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2019.02.024","article-title":"Molecular aspects of depression: a review from neurobiology to treatment","volume":"851","author":"Villas Boas","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105542","article-title":"The receptor hypothesis and the pathogenesis of depression: genetic bases and biological correlates","volume":"167","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib132","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.psychres.2010.04.046","article-title":"Propofol pretreatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test","volume":"185","author":"Wang","year":"2011","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib133","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eurpsy.2011.06.003","article-title":"The European Psychiatric Association (EPA) guidance on suicide treatment and prevention","volume":"27","author":"Wasserman","year":"2012","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069809","article-title":"Antidepressant and neurocognitive effects of isoflurane anesthesia versus electroconvulsive therapy in refractory depression","volume":"8","author":"Weeks","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176032_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175668","article-title":"Correction: antidepressant and neurocognitive effects of isoflurane anesthesia versus electroconvulsive therapy in refractory depression","volume":"12","author":"Weeks","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176032_bib136","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euroneuro.2021.04.010","article-title":"Intranasal administration of transforming growth factor-beta1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: a role of TrkB signaling","volume":"50","author":"Wei","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2023.176032_bib137","series-title":"Depressive disorder (depression)","year":"2023"},{"key":"10.1016\/j.ejphar.2023.176032_bib138","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/17512433.2023.2198703","article-title":"Clinical pharmacological innovation in the treatment of depression","volume":"16","author":"Witkin","year":"2023","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2023.176032_bib141","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","article-title":"NMDAR-independent, cAMP-dependent antidepressant actions of ketamine","volume":"24","author":"Wray","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib142","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2023.176032_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114867","article-title":"Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial","volume":"317","author":"Yan","year":"2022","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2023.176032_bib144","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/175619","article-title":"Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex","volume":"2012","author":"Yang","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejphar.2023.176032_bib145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11684-012-0226-2","article-title":"Tramadol reinforces antidepressant effects of ketamine with increased levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in rat hippocampus","volume":"6","author":"Yang","year":"2012","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2023.176032_bib146","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib147","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-Ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib148","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176032_bib149","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu(2) receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176032_bib150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.176032_bib151","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2023.176032_bib152","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-018-22449-9","article-title":"Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176032_bib153","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","article-title":"Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib154","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-beta1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-beta1","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176032_bib155","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00213-019-05287-z","article-title":"Isoflurane produces antidepressant effects inducing BDNF-TrkB signaling in CUMS mice","volume":"236","author":"Zhang","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2023.176032_bib156","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","article-title":"A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression","volume":"275","author":"Zheng","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2023.176032_bib157","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000356517","article-title":"Akt mediates GSK-3beta phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions","volume":"21","author":"Zhou","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.ejphar.2023.176032_bib158","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neuron.2023.02.017","article-title":"Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter","volume":"111","author":"Zhu","year":"2023","journal-title":"Neuron"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923005447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923005447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:27:24Z","timestamp":1757978844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923005447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":158,"alternative-id":["S0014299923005447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176032","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A synopsis of multitarget therapeutic effects of anesthetics on depression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"176032"}}